All In Biotech

Drug Trial Radar · NCT05238675

A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis

A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study Evaluating Efficacy, Safety and Tolerability of BI 1291583 qd Over at Least 24 Weeks in Patients With Bronchiectasis (AirleafTM)

Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 322 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

322

Actual

Start

Apr 28, 2022

Primary completion

May 1, 2024

Study completion May 30, 2024

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Feb 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with bronchiectasis. People can join the study if they produce sputum and have a history of flare-ups (also called exacerbations). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis. Participants are put into 4 groups randomly, which means by chance. Participants in groups 1, 2, and 3 get different doses of BI 1291583. Participants in group 4 get placebo. Placebo tablets look like BI 1291583 tablets, but do not contain any medicine. Participants take the tablets once a day. Participants are in the study for between 6 months and 1 year. During this time, they visit the study site about 10 times and get about 5 phone calls from the site staff. The doctors document when participants experience flare-ups during the study. The time to the first flare-ups is compared between the treatment groups. Doctors also regularly check participants' health and take note of any unwanted effects.

Conditions

  • Bronchiectasis

Interventions

  • BI 1291583Drug

    BI 1291583

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first pulmonary exacerbation up to 48 weeks after first drug administrationTime frame: Up to week 48

Locations

112 sites in 23 countries. Site status is shown where the registry gives one.

  • Phoenix Medical Group

    Peoria, Arizona

  • Newport Native MD, Inc

    Newport Beach, California

  • University of California Davis

    Sacramento, California

  • Central Florida Pulmonary Group

    Altamonte Springs, Florida

  • Malcom Randall VA Medical Center

    Gainesville, Florida

  • University of Florida College of Medicine

    Jacksonville, Florida

  • University of Kansas Medical Center

    Kansas City, Kansas

  • New York University Langone Medical Center

    New York, New York

  • NewYork-Presbyterian/Weill Cornell Medical Center

    New York, New York

  • Southeastern Research Center

    Winston-Salem, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • Medical University of South Carolina

    Charleston, South Carolina

  • Institute for Translational Oncology Research

    Greenville, South Carolina

  • Metroplex Pulmonary & Sleep Center

    McKinney, Texas

  • Diagnostics Research Group

    San Antonio, Texas

  • University of Texas Health Science Center at Tyler

    Tyler, Texas

  • Macquarie University

    North Ryde, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Lung Research Queensland

    Chermside, Queensland, Australia

  • Mater Research Institute

    South Brisbane, Queensland, Australia

  • Institute for Respiratory Health

    Nedlands, Western Australia, Australia

  • Trialswest

    Spearwood, Western Australia, Australia

  • UNIV UZ Gent

    Ghent, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Medical Center "Zdrave-1"

    Kozloduy, Bulgaria

  • Medica Center Hera - Montana Branch

    Montana, Bulgaria

  • Medical Center ReSpiro Ltd

    Razgrad, Bulgaria

  • SHATPFD "Dr. Dimitar Gramatikov"

    Rousse, Bulgaria

  • Medical Center Hera EOOD

    Sofia, Bulgaria

  • Jewish General Hospital

    Montreal, Migration Data, Canada

  • Centre Hospitalier de l'Universite de Montreal (CHUM)

    Montreal, Quebec, Canada

  • IUCPQ (Laval University)

    Québec, Quebec, Canada

  • Pulmonary Private Practice Kralupy

    Kralupy nad Vltavou, Czechia

  • The First Pulmonary Private Practice

    Prague, Czechia

  • Aalborg Sygehus Syd

    Aalborg, Denmark

  • Hvidovre Hospital

    Hvidovre, Denmark

  • Copenhagen University Hospital, Rigshospitalet

    København Ø, Denmark

  • Odense University Hospital

    Odense, Denmark

  • Sjællands Universitetshospital

    Roskilde, Denmark

  • Vejle University Hospital

    Vejle, Denmark

Showing 40 of 112 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.